David Goodrich
Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. David Goodrich works as Professor of Oncology in the Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. He also works as associate member for Molecular Pharmacology and Cancer Therapeutics Graduate Program, Cancer Genetics CCSG (Cancer Center Support Grant) Program. The main focus of our research is: Understanding molecular mechanisms underlying tumor suppression mediated by the RB1 and TP53 genes, Identifying genes involved in prostate cancer metastasis, Discerning how transcriptionally formed R-loops contribute to cancer initiation and progression
Research Interest
Understanding molecular mechanisms underlying tumor suppression mediated by the RB1 and TP53 genes, Identifying genes involved in prostate cancer metastasis, Discerning how transcriptionally formed R-loops contribute to cancer initiation and progression
Publications
-
Pitzonka L, Wang X, Ullas S, Wolff DW, Goodrich DW, (2013) The THO ribonucleoprotein complex is required for stem cell homeostasis in the adult mouse small intestine. Mol. Cell. Biol 33: 3505-3514
-
Ko HK, Akakura S, Peresie J, Goodrich DW, Foster BA, et al. (2014) A transgenic mouse model for early prostate metastasis to lymph nodes. Cancer Res 74: 945-953
-
Chinnam M, Wang Y, Zhang X, Gold DL, Goodrich DW, et al. (2014) The Thoc1 Ribonucleoprotein and Prostate Cancer Progression. JNCI J Natl Cancer Inst 106: 306
